<?xml version="1.0" encoding="UTF-8" ?> 

<rss version="2.0"> 
<channel> 
<title>Clinical Pharmacology News</title> 
<link>http://www.mdlinx.com/RheumatologyLinx/news.cfm/newspage/1/spec_id/18/subspec_id/362</link> 
<description>Clinical Pharmacology</description> 
<language>en-us</language> 
<copyright>Copyright 2009 MDLinx, Inc.</copyright>










 



<item> 
<title><![CDATA[Effect of alendronate on bone metabolic indices and bone mineral density in patients treated with high-dose glucocorticoid: A prospective study]]></title> 
<link>http://www.mdlinx.com/RheumatologyLinx/xml-article.cfm/2960199</link> 
<pubDate>11/25/2009</pubDate> 
<description><![CDATA[<b>Osteoporosis International</b>]]></description> 
<guid>http://www.mdlinx.com/RheumatologyLinx/xml-article.cfm/2960199</guid>
</item> 
 

<item> 
<title><![CDATA[Treatment of osteoporosis: Recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity]]></title> 
<link>http://www.mdlinx.com/RheumatologyLinx/xml-article.cfm/2960200</link> 
<pubDate>11/25/2009</pubDate> 
<description><![CDATA[<b>Osteoporosis International</b>]]></description> 
<guid>http://www.mdlinx.com/RheumatologyLinx/xml-article.cfm/2960200</guid>
</item> 


 

<item> 
<title><![CDATA[Urinary deoxypyridinoline is a BMD-independent marker for prevalent vertebral fractures in postmenopausal women treated with glucocorticoid]]></title> 
<link>http://www.mdlinx.com/RheumatologyLinx/xml-article.cfm/2960197</link> 
<pubDate>11/25/2009</pubDate> 
<description><![CDATA[<b>Osteoporosis International</b>]]></description> 
<guid>http://www.mdlinx.com/RheumatologyLinx/xml-article.cfm/2960197</guid>
</item> 
 
 


  


</channel> 
</rss>

